Highwise Health
U.S.

Elinzanetant FDA Review Granted for Cancer Treatment

The FDA has accepted a request to review elinzanetant for managing hot flashes in breast cancer patients on endocrine therapy.

Updated on Sept. 28, 2026 in Cancer

Bold flat-color editorial illustration showing a glass beaker and molecular compound, representing FDA pharmaceutical review in a clinical context.
The FDA has granted Priority Review to the drug elinzanetant, potentially offering a non-hormonal treatment option for breast cancer patients experiencing hot flashes during endocrine therapy. AI Illustration. Upload story photo >

Live Poll

Do you trust that pharmaceutical companies are doing enough to address breast cancer treatment side effects?

The FDA granted Priority Review to a supplemental application for the drug elinzanetant. This treatment, already approved for menopausal hot flashes, aims to provide a new option for patients receiving endocrine therapy for breast cancer.

Why it matters

Currently, there are no FDA-approved treatments for vasomotor symptoms in this patient population, leaving a significant gap in supportive care. Approval would offer a needed strategy for managing symptoms during multi-year breast cancer treatment regimens.

In the 52-week OASIS-4 Phase 3 trial of 474 women, elinzanetant demonstrated a reduction in the frequency of vasomotor symptoms compared to placebo. Study investigators evaluated the daily 60mg dose, though the trial's full implications for broader oncological outcomes are still evolving.

The players

U.S. Food and Drug Administration

The federal agency responsible for regulating pharmaceuticals, medical devices, and public health safety standards in the United States.

Bayer

A global life sciences company that develops pharmaceuticals and consumer health products, including treatments for menopause and oncology supportive care.

The details

Elinzanetant acts by targeting the brain's thermoregulatory center to address vasomotor symptoms, which are common side effects of endocrine therapy. In the 52-week double-blind study, researchers monitored participants for adverse events, which included headache, fatigue, and somnolence. This medication potentially provides a non-hormonal approach to symptom management for patients undergoing endocrine therapy, which is typically required for at least five years.

Timeline

  1. June 2025: OASIS-4 trial findings were published in the NEJM.

  2. October 2025: FDA approved elinzanetant for menopausal hot flashes.

  3. September 28, 2026: Bayer announced the FDA accepted the supplemental application.

Health Landscape

This development addresses a critical gap in supportive care for the 70% of breast cancer cases that are hormone receptor-positive. It builds upon the OASIS-4 Phase III trial to provide a pathway for symptom management where no approved pharmacological options currently exist.

Patients currently experiencing vasomotor symptoms while on endocrine therapy should speak with their oncologist about whether future FDA-approved options may be appropriate for their treatment plan. Keep a log of symptom frequency to discuss during your next consultation, as this data remains essential for personalized care decisions.

The takeaway

Elinzanetant is currently undergoing regulatory review as a potential treatment for vasomotor symptoms in patients receiving endocrine therapy. If you are experiencing persistent hot flashes during cancer treatment, ask your physician about emerging supportive care options to discuss at your next visit.

Further reading

For more information on current treatment standards, visit Cancer.

Live Poll

Do you trust that pharmaceutical companies are doing enough to address breast cancer treatment side effects?

Elinzanetant FDA Review Granted for Cancer Treatment | Highwise Health